Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse

Abstract

Objective

In the era of powerful immunosuppression, opportunistic infections are an increasing concern in systemic lupus erythematosus. One of the best-studied opportunistic infections is Pneumocystis pneumonia; however, the prevalence of Pneumocystis pneumonia in systemic lupus erythematosus is not clearly defined. This study evaluates the prevalence of Pneumocystis pneumonia in hospitalized systemic lupus erythematosus patients, with a focus on validating the Pneumocystis pneumonia and systemic lupus erythematosus diagnoses with clinical information.

Methods

This retrospective cohort study evaluates the prevalence of Pneumocystis pneumonia in all systemic lupus erythematosus patients treated at Columbia University Medical Center-New York Presbyterian Hospital between January 2000 and September 2014, using electronic medical record data. Patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and patients with renal transplants (including both early and late post-transplant patients) represented immunocompromised control groups. Patients with systemic lupus erythematosus, Pneumocystis pneumonia, HIV/AIDS, or renal transplant were identified using diagnostic codes from the International Classification of Diseases, Ninth Revision (ICD-9).

Results

Out of 2013 hospitalized systemic lupus erythematosus patients, nine had presumed Pneumocystis pneumonia, yielding a low prevalence of Pneumocystis pneumonia in systemic lupus erythematosus of 0.45%. Three of the nine Pneumocystis pneumonia cases were patients with concomitant systemic lupus erythematosus and HIV/AIDS. Only one of these nine cases was histologically confirmed as Pneumocystis pneumonia, in a patient with concomitant systemic lupus erythematosus and HIV/AIDS and a CD4 count of 13 cells/mm³. The prevalence of Pneumocystis pneumonia in renal transplant patients and HIV/AIDS patients was 0.61% and 5.98%, respectively.

Conclusion

Given the reported high rate of adverse effects to trimethoprim-sulfamethoxazole in systemic lupus erythematosus and the low prevalence of Pneumocystis pneumonia in hospitalized systemic lupus erythematosus patients, our data do not substantiate the need for Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus patients, except in those with concurrent HIV/AIDS.

Keywords

Systemic lupus erythematosus (SLE)opportunistic infections electronic medical records database HIV

Get full access to this article

View all access options for this article.

References

Zandman-Goddard

Shoenfeld

. Infections and SLE. Autoimmunity 2005; 38: 473–485.

Morris

Lundgren

Masur

et al.

Current epidemiology of Pneumocystis pneumonia. Emerging Infect Dis 2004; 10: 1713–1720.

Fuggle SV, Belger MA, Johnson RJ, Ray TC, Morris PJ. A new national allocation scheme for adult kidneys in the United Kingdom. United Kingdom Transplant Support Service Authority (UKTSSA) Users’ Kidney Advisory Group and its Task Forces. Clin Transplants 1998: 107–113.

Wang

Partovi

Levy

Shapiro

Yoshida

Greanya

. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transplant Infect Dis 2012; 14: 519–525.

Martin-Garrido

Carmona

Specks

Limper

. Pneumocystis pneumonia in patients treated with rituximab. Chest 2013; 144: 258–265.

Yale

Limper

. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 5–13.

Morris

Johnson

Fuggle

Belger

Briggs

. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Lancet 1999; 354: 1147–1152.

Frank

Hamburger

Lawley

Kimberly

Plotz

. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 1979; 300: 518–523.

Godeau

Coutant-Perronne

Le Thi Huong

et al.

Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994; 21: 246–251.

10.

Rosner

Ginzler

Diamond

et al.

A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982; 25: 612–617.

11.

Ginzler

Diamond

Kaplan

Weiner

Schlesinger

Seleznick

. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 37–44.

12.

Ward

Donald

. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999; 42: 780–789.

13.

Feldman

Hiraki

Winkelmayer

et al.

Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 2015; 67: 1577–1585.

14.

Murray

Schmajuk

Trupin

et al.

National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia. PLoS One 2016; 11: e0144918–e0144918.

15.

Gupta

Zachariah

Roppelt

Patel

Gruber

. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol 2008; 14: 267–272.

16.

Pope

Jerome

Fenlon

Krizova

Ouimet

. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 480–484.

17.

Petri

Allbritton

. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol 1992; 19: 265–269.

18.

Muller

Richardson

Walmsley

. Trimethoprim-sulfamethoxazole induced aseptic meningitis in a renal transplant patient. Clin Nephrol 2001; 55: 80–84.

19.

Escalante

Stimmler

. Trimethoprim-sulfamethoxasole induced meningitis in systemic lupus erythematosus. J Rheumatol 1992; 19: 800–802.

20.

Price

Venables

. Drug-induced lupus. Drug Saf 1995; 12: 283–290.

21.

Roux

Gonzalez

Roux

et al.

Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect 2014; 44: 185–198.

22.

Lim SS, Drenkard C. Epidemiology of lupus: an update. Current Opinion in Rheumatology 2015; 27: 427–432.

23.

Lim

Drenkard

McCune

et al.

Population-based lupus registries: advancing our epidemiologic understanding. Arthritis Rheum 2009; 61: 1462–1466.

24.

Karve

Candrilli

Kappelman

Tolleson-Rinehart

Tennis

Andrews

. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease. J Pediatr 2012; 161: 662–670.e2.

25.

Klein

Ray

Carpenter

et al.

Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010; 28: 1062–1068.

26.

Broder

Khattri

Patel

Putterman

. Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality. J Rheumatol 2011; 38: 2382–2389.

27.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

28.

Tan

Cohen

Fries

et al.

The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

29.

Petri

Orbai

Alarcon

et al.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

30.

Ines

Silva

Galindo

et al.

Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort. Arthritis Care Res 2015; 67: 1180–1185.

31.

O’Malley

Cook

Price

Wildes

Hurdle

Ashton

. Measuring diagnoses: ICD code accuracy. Health Serv Res 2005; 40: 1620–1639.

32.

Carmona

Limper

. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 2011; 5: 41–59.

33.

Kitahata MM, et al. Ascertainment and verification of end-stage renal disease and end-stage liver disease in the North American AIDS cohort collaboration on research and design. AIDS Research and Treatment 2015; 2015: 923194.

34.

Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S1–S157.

35.

Cregan

Yamamoto

Lum

VanDerHeide

MacDonald

Pulliam

. Comparison of four methods for rapid detection of Pneumocystis carinii in respiratory specimens. J Clin Microbiol 1990; 28: 2432–2436.

36.

Azoulay

Bergeron

Chevret

Bele

Schlemmer

Menotti

. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009; 135: 655–661.

37.

Takahashi

Goto

Endo

et al.

Pneumocystis carinii carriage in immunocompromised patients with and without human immunodeficiency virus infection. J Med Microbiol 2002; 51: 611–614.

38.

Savarino

Boelaert

Cassone

Majori

Cauda

. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003; 3: 722–727.

39.

Raoult

Houpikian

Tissot Dupont

Riss

Arditi-Djiane

Brouqui

. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 1999; 159: 167–173.

40.

Savarino

Di Trani

Donatelli

Cauda

Cassone

. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006; 6: 67–69.

41.

Campbell

Clayton

. A scoring system to screen elderly potential kidney transplant recipients: a simple tool for a complex task. Kidney Int 2015; 88: 5–6.

42.

Wagner

Skripchenko

Thompson-Montgomery

. Quinacrine enhances vesicular stomatitis virus inactivation and diminishes hemolysis of dimethylmethylene blue-phototreated red cells. Photochem Photobiol 2002; 76: 514–517.

43.

Ornstein

Sperber

. The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Arthritis Rheum 1996; 39: 157–161.

44.

Podrebarac TA, Jovaisas A, Karsh J. Pneumocystis carinii pneumonia after discontinuation of hydroxychloroquine in 2 patients with systemic lupus erythematosus. J Rheumatol. 1996; 23: 199–200.

45.

Ben-Zvi

Kivity

Langevitz

Shoenfeld

. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42: 145–153.

46.

O’Brien

Allison

Hahn

. Evidence for intercalation of chloroquine into DNA. Biochim Biophys Acta 1966; 129: 622–624.

47.

O’Brien

Olenick

Hahn

. Reactions of quinine, chloroquine, and quinacrine with DNA and their effects on the DNA and RNA polymerase reactions. Proc Natl Acad Sci U S A 1966; 55: 1511–1517.

48.

Allison

O’Brien

Hahn

. DNA: reaction with chloroquine. Science 1965; 149: 1111–1113.

49.

Roskoski

Jr Jaskunas

. Chloroquine and primaquine inhibition of rat liver cell-free polynucleotide-dependent polypeptide synthesis. Biochem Pharmacol 1972; 21: 391–399.

50.

Ciak

Hahn

. Chloroquine: mode of action. Science 1966; 151: 347–349.

51.

Azevedo

Castro

Paula

Ianhez

David-Neto

. Mycophenolate mofetil may protect against Pneumocystis carinii pneumonia in renal transplanted patients. Rev Inst Med Trop Sao Paulo 2005; 47: 143–145.